Armata Pharmaceuticals Achieves Key Progress Across Clinical, Regulatory and Manufacturing Activities Supporting Planned Phase 3 Initiation of AP-SA02

FDA submissions address all feedback on clinical, CMC, and regulatory topics from the End-of-Phase 2 meeting

Four AP-SA02 engineering runs completed; clinical trial material production is the next planned manufacturing step